Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 29  •  04:00PM ET
24.92
Dollar change
+0.03
Percentage change
0.13
%
Category
Global or ExUS Equities - Industry Sector
Asset Type
Equities (Stocks)
Tags
Return% 1Y
16.07%
Total Holdings
23
Perf Week
1.61%
Sponsor
Amplify Investments
ETF Type
Tags
Return% 3Y
-
AUM
4.24M
Perf Month
5.66%
Fund Family
Bond Type
Tags
Return% 5Y
-
NAV/sh
Perf Quarter
-3.99%
Index
VettaFi Weight Loss Drug & Treatment Ind...
Average Maturity
Tags
Return% 10Y
52W High
27.28 -8.64%
Perf Half Y
-4.06%
Index Weighting
Commodity Type
Tags
-
Return% SI
52W Low
21.70 14.85%
Perf YTD
-1.18%
Active/Passive
Quant Type
Tags
-
Flows% 1M
0.00%
Volatility
2.75% 1.33%
Perf Year
13.72%
ESG Type
Tags
-
Flows% 3M
0.00%
ATR (14)
0.45
Perf 3Y
-
Dividend Type
Sector/Theme
Flows% YTD
57.69%
RSI (14)
55.52
Perf 5Y
-
Structure Type
Region
Flows% 1Y
Beta
0.41
Perf 10Y
-
Expense
0.59%
Growth/Value
SMA20
0.96%
Flows% 3Y
Rel Volume
0.31
Prev Close
24.89
Inverse/Leveraged
Market Cap
SMA50
1.77%
Flows% 5Y
Avg Volume
1.21K
Price
24.92
IPO
May 21, 2024
Option/Short
No / No
SMA200
1.20%
Trades
Volume
372
Change
0.13%
Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.